Columbamine

Columbamine at a Glance

Columbamine is a minor protoberberine alkaloid — one of the yellow isoquinoline alkaloids that colour the roots and rhizomes of barberry, goldthread (coptis) and related plants. It is a close structural relative of berberine, and in every plant that makes it, it occurs as a low-abundance companion to berberine rather than a lead compound.

Almost everything known about columbamine comes from isolated-compound laboratory studies — mostly in-vitro anticancer screens, one old rodent liver study, and an enzyme-inhibition assay. There are no human trials of columbamine, and, like berberine, it is a quaternary alkaloid cation with poor expected oral absorption, so the concentrations used in cell work should not be assumed reachable in people. This is a data-thin molecule, and the honest posture below reflects that.

Columbamine vs. Jatrorrhizine

The single most useful thing to know about columbamine’s structure is that it is a positional isomer of jatrorrhizine — the two molecules share the same formula (C₂₀H₂₀NO₄⁺, ~338 g/mol) and the same three methoxy groups, and differ only in where the one free hydroxyl sits on the A-ring:

• Columbamine — hydroxyl at C-2, methoxy groups at C-3, C-9 and C-10 (2-hydroxy-3,9,10-trimethoxy).
• Jatrorrhizine — hydroxyl at C-3, methoxy groups at C-2, C-9 and C-10 (3-hydroxy-2,9,10-trimethoxy).

That single swapped position is the entire chemical difference. Both are, in turn, near-relatives of berberine (which closes the same C-2/C-3 oxygens into a methylenedioxy ring) and of palmatine (which methylates columbamine’s free hydroxyl). Because the isomers are so similar, they routinely co-occur, co-elute and are studied together, and much of the older “Coptis alkaloid” literature does not cleanly separate their individual contributions.

What It's Used For

Columbamine’s evidence base is small and preclinical: a cluster of in-vitro (and a few xenograft) cancer-cell studies, a single 1988 rodent hepatoprotective report on a three-alkaloid extract, and one cholinesterase-inhibition assay.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here rests on isolated-compound, non-human data, so the scores are deliberately low.

01Anticancer / antiproliferativeShaky30%In-vitro + a few xenograft studies (osteosarcoma, colon, HCC) ^{1,2,3Reference 1Bao M et al. · 2012Columbamine suppresses the proliferation and neovascularization of metastatic osteosarcoma U2OS cells with low cytotoxicityView study →Reference 2Lei C et al. · 2019Columbamine suppresses the proliferation and malignization of colon cancer cells via abolishing Wnt/β-catenin signaling pathwayView study →Reference 3Lin Z et al. · 2019Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathwaysView study →}

02HepatoprotectiveShaky18%One 1988 rat study of a three-alkaloid extract ^{5Reference 5Virtanen P et al. · 1988AnimalNatural protoberberine alkaloids from Enantia chlorantha: palmatine, columbamine and jatrorrhizine for thioacetamide-traumatized rat liverView study →}

03Cholinesterase inhibitionShaky16%Single in-vitro assay, IC₅₀ ≈ 48 µM ^{4Reference 4Yusoff M et al. · 2014Anticholinesterase inhibitory activity of quaternary alkaloids from Tinospora crispaView study →}

Mechanisms

The mechanisms are real observations but scattered across different cell systems; no unifying, replicated pathway has been established for columbamine, and none has been tested in humans.

Pharmacokinetics

Columbamine is a quaternary protoberberine cation, the same physicochemical class as berberine, and it has been confirmed in vivo as a P-glycoprotein substrate — ranked alongside jatrorrhizine in efflux capacity among six protoberberines, using P-gp-knockout mice ^{6Reference 6Zhang YT et al. · 2019Different structures of berberine and five other protoberberine alkaloids that affect P-glycoprotein-mediated efflux capacityView study →}. Active intestinal efflux, together with the low solubility and extensive first-pass metabolism typical of this alkaloid class, predicts poor oral bioavailability in the berberine mould, though no dedicated human pharmacokinetic study of columbamine exists. The practical caveat is the same one that dogs berberine: micromolar potency in a dish does not imply those concentrations are reachable in blood after an oral dose ^{6Reference 6Zhang YT et al. · 2019Different structures of berberine and five other protoberberine alkaloids that affect P-glycoprotein-mediated efflux capacityView study →}.

Clinical Trials

There are no clinical trials of columbamine — completed, ongoing or registered. Its entire evidence base is in-vitro and rodent.

Last checked: July 2026.

Isolate vs. Plant Studies

Columbamine sits at the difficult end of the isolate-vs-plant spectrum. Its anticancer and enzyme studies do use the isolated molecule ^{1,2,3,4Reference 1Bao M et al. · 2012Columbamine suppresses the proliferation and neovascularization of metastatic osteosarcoma U2OS cells with low cytotoxicityView study →Reference 2Lei C et al. · 2019Columbamine suppresses the proliferation and malignization of colon cancer cells via abolishing Wnt/β-catenin signaling pathwayView study →Reference 3Lin Z et al. · 2019Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathwaysView study →Reference 4Yusoff M et al. · 2014Anticholinesterase inhibitory activity of quaternary alkaloids from Tinospora crispaView study →} — a genuine strength as far as it goes — but they are all in cell culture or mice, so “isolated compound” here means isolated in a dish, not isolated in a human trial. Its one whole-organism report is the opposite case: a three-alkaloid plant extract in rats, where columbamine cannot be disentangled from palmatine and jatrorrhizine ^{5Reference 5Virtanen P et al. · 1988AnimalNatural protoberberine alkaloids from Enantia chlorantha: palmatine, columbamine and jatrorrhizine for thioacetamide-traumatized rat liverView study →}. And in its source plants — barberry root, goldthread rhizome — columbamine is a minor alkaloid dwarfed by berberine, so the traditional and pharmacological reputation of those roots belongs to the alkaloid mixture led by berberine, not to columbamine ^{8Reference 8Mokhber-Dezfuli N et al. · 2014Phytochemistry and pharmacology of Berberis speciesView study →}. Read columbamine’s data as early molecular signals, not as evidence for any plant.

Prevalence in Nature

Columbamine occurs across the same berberine-producing plant families that make the other protoberberines, always as a minor constituent of the yellow root/rhizome alkaloid fraction. Documented sources include several Berberis (barberry) species ^{8Reference 8Mokhber-Dezfuli N et al. · 2014Phytochemistry and pharmacology of Berberis speciesView study →}, Coptis chinensis (Chinese goldthread) ^{7Reference 7Wu L et al. · 2024A biosynthetic network for protoberberine production in Coptis chinensisView study →}, and the calumba vine Jateorhiza palmata — the plant that gave the molecule its name. It also turns up in Tinospora crispa ^{4Reference 4Yusoff M et al. · 2014Anticholinesterase inhibitory activity of quaternary alkaloids from Tinospora crispaView study →} and the African tree Enantia chlorantha ^{5Reference 5Virtanen P et al. · 1988AnimalNatural protoberberine alkaloids from Enantia chlorantha: palmatine, columbamine and jatrorrhizine for thioacetamide-traumatized rat liverView study →}. In every case it accompanies the dominant berberine rather than replacing it, and most phytochemical surveys report it qualitatively; a clean, quantified concentration for columbamine is rarely given, so no per-source figures are tabulated here (see the gaps tracker).

Biosynthetically, columbamine is a branch point in the benzylisoquinoline pathway: it is formed by oxidation of (S)-tetrahydrocolumbamine, and a dedicated columbamine O-methyltransferase methylates its free hydroxyl to make palmatine ^{7Reference 7Wu L et al. · 2024A biosynthetic network for protoberberine production in Coptis chinensisView study →}. Notably, columbamine is not converted onward to berberine in Coptis — berberine is built by a separate methylenedioxy-bridge route from the same tetrahydro precursor — so columbamine and berberine are parallel end-products, not sequential ones ^{7Reference 7Wu L et al. · 2024A biosynthetic network for protoberberine production in Coptis chinensisView study →}.

Discovery & Synthesis

Columbamine takes its name from calumba (columbo) root, Jateorhiza palmata, one of the plants from which it was obtained; the precise date of first isolation is not well documented in the modern literature. Its biosynthesis in plants is comparatively well characterised — the (S)-tetrahydrocolumbamine oxidation and the columbamine O-methyltransferase step have been mapped in Coptis chinensis ^{7Reference 7Wu L et al. · 2024A biosynthetic network for protoberberine production in Coptis chinensisView study →} — but there is no notable total synthesis on record, and it is not manufactured commercially. When columbamine is needed it is obtained by chromatographic isolation from berberine-rich root material as a minor fraction, which is one reason it remains so lightly studied.

Patents: not yet researched.

Toxicity & Safety

Columbamine carries a low flag — a cautious call rather than a clean bill of health. It is a minor congener of well-tolerated berberine, its poor oral absorption limits systemic exposure, and no specific toxicity signal has been reported for it. But that “low” rests largely on the absence of testing: there is no human safety data, no isolate genotoxicity or repeat-dose package, and its interaction and reproductive profiles are simply uncharacterised.

Safety at a Glance

✅ Low / no toxicityDrug interactions

• No specific toxicity signal reported, and only minor amounts are ever ingested from berberine-rich herbs.
• A P-glycoprotein substrate ^{6Reference 6Zhang YT et al. · 2019Different structures of berberine and five other protoberberine alkaloids that affect P-glycoprotein-mediated efflux capacityView study →} — like other protoberberines it could, in principle, participate in transporter-level drug interactions, though this has not been studied for columbamine specifically.
• Protoberberine class-cautions may apply but are untested here. Berberine’s known cautions (drug-metabolising-enzyme interactions; bilirubin displacement / neonatal risk) have not been characterised for columbamine — treat its safety as unknown rather than proven benign.
• No human data at all — every finding is in-vitro or rodent.

Dosage

There is no established or studied human dose for columbamine. Laboratory work has used low-micromolar concentrations in cell culture (for example, an anti-osteosarcoma IC₅₀ near 21 µM ^{1Reference 1Bao M et al. · 2012Columbamine suppresses the proliferation and neovascularization of metastatic osteosarcoma U2OS cells with low cytotoxicityView study →}) and undocumented extract doses in rodents ^{5Reference 5Virtanen P et al. · 1988AnimalNatural protoberberine alkaloids from Enantia chlorantha: palmatine, columbamine and jatrorrhizine for thioacetamide-traumatized rat liverView study →} — figures that describe experiments, not intake. Human exposure is limited to the trace amounts present in berberine-rich herbs such as barberry and goldthread, where columbamine is a minor alkaloid. These are research figures and are not a personal recommendation.

References

1. Bao M, Cao Z, Yu D, Fu S, Zhang G, Yang P, et al. (2012). Columbamine suppresses the proliferation and neovascularization of metastatic osteosarcoma U2OS cells with low cytotoxicity. Toxicology Letters, 215(3), 174–180. https://pubmed.ncbi.nlm.nih.gov/23124089/
2. Lei C, Yao Y, Shen B, Liu J, Pan Q, Liu N, et al. (2019). Columbamine suppresses the proliferation and malignization of colon cancer cells via abolishing Wnt/β-catenin signaling pathway. Cancer Management and Research, 11, 8635–8645. https://pubmed.ncbi.nlm.nih.gov/31572013/
3. Lin Z, Li S, Guo P, Wang L, Zheng L, Yan Z, et al. (2019). Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways. Life Sciences, 218, 197–204. https://pubmed.ncbi.nlm.nih.gov/30582951/
4. Yusoff M, Hamid H, Houghton P (2014). Anticholinesterase inhibitory activity of quaternary alkaloids from Tinospora crispa. Molecules, 19(1), 1201–1211. https://pubmed.ncbi.nlm.nih.gov/24448061/
5. Virtanen P, Lassila V, Njimi T, Mengata DE (1988). Natural protoberberine alkaloids from Enantia chlorantha: palmatine, columbamine and jatrorrhizine for thioacetamide-traumatized rat liver. Acta Anatomica, 131(2), 166–170. https://pubmed.ncbi.nlm.nih.gov/3369286/
6. Zhang YT, Yu YQ, Yan XX, Wang WJ, Tian XT, Wang L, et al. (2019). Different structures of berberine and five other protoberberine alkaloids that affect P-glycoprotein-mediated efflux capacity. Acta Pharmacologica Sinica, 40(1), 133–142. https://pubmed.ncbi.nlm.nih.gov/30442987/
7. Wu L, Zhao B, Deng Z, Wang B, Yu Y (2024). A biosynthetic network for protoberberine production in Coptis chinensis. Horticulture Research, 11(2), uhad259. https://pubmed.ncbi.nlm.nih.gov/38282690/
8. Mokhber-Dezfuli N, Saeidnia S, Gohari AR, Kurepaz-Mahmoodabadi M (2014). Phytochemistry and pharmacology of Berberis species. Pharmacognosy Reviews, 8(15), 8–15. https://pubmed.ncbi.nlm.nih.gov/24600191/

View all 8 references▾